Core Viewpoint - Duori Pharmaceutical (301075) has completed the transfer of shares, with 23.68 million shares (29.6% of total shares) being transferred, resulting in a change of control to Wang Qingtai, Cui Zihao, and Cao Xiaobing [1] Group 1: Share Transfer Details - The share transfer was confirmed by the China Securities Depository and Clearing Corporation on December 8, with the transfer date being December 5 [1] - The transferred shares are classified as unrestricted circulating shares [1] - Following the transfer, the new controlling shareholders hold a combined 29.6% of the company's shares and corresponding voting rights [1] Group 2: Voting Rights and Agreements - According to the share transfer agreement, Tibet Jiakang has waived its voting rights for 19.44 million shares (24.3% of total shares) until the completion of the tender offer [1] - The waiver of voting rights will not be restored before the completion of the tender offer unless there is written agreement from both the transferor and transferee [1] - After the transfer and waiver, Tibet Jiakang and Zhoushan Qingchang hold a combined 11.98% of the voting rights [1]
多瑞医药控股股东、实际控制人变更为王庆太、崔子浩、曹晓兵